PR
Prolaio
Verified
Chicago, United States · HealthTech
HealthTech Seed Founded 2022
medical office modern

Overview

Prolaio is a healthtech software company based in Chicago, United States, founded in 2022. The company develops clinical trial research software designed to process and analyse data generated during clinical trials.

The company addresses the challenge of translating complex clinical data into actionable insights within the clinical research sector. Clinical trials generate substantial volumes of data that require sophisticated analysis to inform medical decision-making and advance treatment development.

Activities and products

Prolaio's primary offering is clinical trial research software. The platform is designed to support clinical innovation by enabling researchers and organisations to extract meaningful insights from trial data. The company's focus extends to cardiovascular care, where it is expanding its team to develop solutions tailored to this therapeutic area.

Stage and funding

Prolaio is at seed stage and has raised seed funding. The company was founded in 2022 and remains in early-stage development. Beyond confirmation of seed funding, specific details regarding investors or funding amounts are not verified.

Photograph: Vitaly Gariev / Unsplash

Company details

Legal name
Prolaio
Website
www.prolaio.com
Headquarters
Chicago, United States
Founded
2022
Sector
HealthTech
Funding stage
Seed

Verification

Verified profile
Reviewed by Rohan Kapadia on 10 June 2026. Primary source: www.prolaio.com. For corrections or removal, contact [email protected].